Genmab AS (WBO:GMAB) Stock News, Headlines & Updates
Genmab AS Stock News from GuruFocus
- 1
Jul 16, 2025
Genmab (GMAB) Reports Strong Darzalex Sales in Q2 2025
GuruFocus News • 6:55am
Jul 08, 2025
Truist Securities Maintains Buy Rating and Raises Price Target on GMAB | GMAB Stock News
GuruFocus News • 11:32am
Jun 16, 2025
Genmab (GMAB) Reports Promising Results from Epcoritamab Trial | GMAB Stock News
GuruFocus News • 7:30pm
Jun 15, 2025
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autol
GuruFocus News • 4:15am
Jun 06, 2025
JPMorgan Adjusts Price Target on Genmab (GMAB) Stock | GMAB Stock News
GuruFocus News • 12:15pm
Jun 02, 2025
Genmab (GMAB) Stock Moves on Positive Trial Results and Share Buyback Update
GuruFocus News • 5:50pm
Genmab (GMAB) Announces Promising Rina-S Data from Endometrial Cancer Trial | GMAB Stock News
GuruFocus News • 2:00pm
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Tr
GuruFocus News • 1:45pm
May 29, 2025
RBC Capital Adjusts Price Target for Genmab (GMAB) Following Q1 Results | GMAB Stock News
GuruFocus News • 8:31am
May 22, 2025
Genmab AS (GMAB) to Present New Research at ASCO 2025 Annual Meeting | GMAB stock news
GuruFocus News • 6:01pm
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Business Wire • 5:00pm
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting | GMAB Stock News
GuruFocus News • 4:16pm
May 14, 2025
Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress
Business Wire • 10:00am
Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress | GMAB Stock News
GuruFocus News • 9:30am
Genmab (GMAB) Receives Revised Price Target from H.C. Wainwright | GMAB Stock News
GuruFocus News • 5:45am
May 09, 2025
Genmab (GMAB) Upgraded to Buy, Undervalued with Growth Potential | GMAB Stock News
GuruFocus News • 5:16am
Genmab AS (GMAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives
GuruFocus News • 1:36am
Q1 2025 Genmab A/S Earnings Call Transcript
GuruFocus News • 11:20pm
May 08, 2025
GMAB Expands Global Reach with Key Approvals and Promising Data | GMAB Stock News
GuruFocus News • 10:30am
May 02, 2025
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R²) in Patients with Relapsed/Refractory Follic
GuruFocus News • 7:45pm
Apr 28, 2025
HSBC Adjusts Price Target for Genmab (GMAB) Amid Potential Earnings Challenges | GMAB Stock News
GuruFocus News • 6:18am
- 1
Show
Entries
Headlines
Total 0- 1
No recent news